CliffBio
biologic

Monjuvi

tafasitamab-cxix

Loss of exclusivityJuly 2032projected — 12-year biologic exclusivity estimate
CompanyIncyte Corporation

Drug detail

Brand nameMonjuvi
Active ingredienttafasitamab-cxix
Strength200MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2020
Marketing statusRx

More from Incyte Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Monjuvi patent cliff — loss of exclusivity July 2032 | CliffBio